IVIG Therapy

Course Overview

Course Outline

1. Introduction 
2. Intravenous Immunoglobulin (IVIG) Therapy 
   1. Prevalence 
   2. Indications 
   3. Options 
   4. Usage 
   5. Clinical Criterium 
   6. Side Effects and Complications 
   7. Average Cost 
   8. Self-Management 
   9. Alternatives 
   10. Limited Access 
3. IVIG Therapy Special Considerations 
   1. Neonates 
   2. Pediatrics 
   3. Pregnant Populations 
4. IVIG Therapy Use and IV Management and Complications 
5. Telemonitoring in Inpatient and Outpatient IVIG Therapy 
6. Nursing Considerations 
7. Client Education 
8. Upcoming Research 
9. Case Study 
10. Conclusion 

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss IVIG Therapy. It will take the average learner 180 minutes to complete and awards 3 contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

1. Describe common side effects, including severe possible side effects, of IVIG therapy 
2. Describe educational strategies for IVIG therapy use 
3. List alternatives to IVIG therapy 
4. Explain management techniques for IVIG therapy complications 
5. Discuss recommendations for IVIG therapy use and monitoring in outpatient, non-emergent settings 

Target Audience

• Registered Nurses (RN)
• Advanced Practice Registered Nurses (APRN)
• Licensed Practical Nurses (LPN/LVN)

Requirement for Completion

1. Enrollment in the course by the learner
2. Read and learn all course materials
3. Complete the course evaluation
4. Attest and testify learning of the course materials

Accreditations + Approvals

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.